AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18971914 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 3 g per day orally for 3 months
Number of subjects: 84
Study 18971914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 16128125 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 2 g of first generation cephalosporins (Group 1, n = 200)
Number of subjects: 450
Study 16128125 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2, n = 250)
Number of subjects: 450
Study 12063985 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b plus ribavirin for 48 weeks
Number of subjects: 117
Study 12063985 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha-2b plus placebo for 24 weeks followed by 24 weeks of combined therapy
Number of subjects: 117
Study 9814724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (0.25mg/kg b.i.d.)
Number of subjects: 817
Study 9814724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 817
Study 9814724 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine or Placebo
Number of subjects: 817
Study 9814724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 817
Study 7649921 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 12
Study 7649921 — intervention group
Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 12
Study 2672898 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 0.5% bupivacaine with epinephrine, 5 micrograms/ml
Number of subjects: 26
Study 2672898 — intervention group
Group type: COMPARATOR
Intervention: 20 ml preservative-free saline
Number of subjects: 26
Study 786663 — intervention group
Group type: EXPERIMENTAL
Intervention: Prorenoate potassium 45 mg
Number of subjects: 6
Study 786663 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg
Number of subjects: 6
Study 786663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30185568 — intervention group
Group type: EXPERIMENTAL
Intervention: Hashimoto's thyroiditis (HT) cohort
Number of subjects: 1268
Study 30185568 — intervention group
Group type: EXPERIMENTAL
Intervention: Hashimoto's thyroiditis (HT) cohort aged ≥50 years
Number of subjects: 1268
Study 30185568 — intervention group
Group type: EXPERIMENTAL
Intervention: Hashimoto's thyroiditis (HT) cohort women
Number of subjects: 1268
Study 30185568 — intervention group
Group type: EXPERIMENTAL
Intervention: Hashimoto's thyroiditis (HT) cohort without thyroxine treatment
Number of subjects: 1268
Study 30185568 — intervention group
Group type: EXPERIMENTAL
Intervention: Hashimoto's thyroiditis (HT) cohort with thyroxine treatment
Number of subjects: 1268
Study 27639827 — intervention group
Group type: EXPERIMENTAL
Intervention: POs‐Ca chewing gum
Number of subjects: 37
Study 27639827 — intervention group
Group type: EXPERIMENTAL
Intervention: POs‐Ca+F chewing gum
Number of subjects: 37
Study 27639827 — intervention group
Group type: COMPARATOR
Intervention: Control chewing gum
Number of subjects: 37
Study 24518166 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year nutrition-based comprehensive intervention weight-loss program
Number of subjects: 326
Study 24518166 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 326
Study 24518166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 326
Study 22898328 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group (n=27) including exercise advice by a physiotherapist six times during pregnancy
Number of subjects: 54
Study 22898328 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=27) without additional exercise advice
Number of subjects: 54
Study 21075912 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral night splints for 3 weeks
Number of subjects: 22
Study 21075912 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise regimen for 3 weeks
Number of subjects: 22
Study 18544992 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxotere plus prednisolone (30 mg/m2 weekly during 5 of 6 weeks + prednisolone 5 mg orally twice daily)
Number of subjects: 134
Study 18544992 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (5 mg orally twice daily)
Number of subjects: 134
Study 18544992 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxotere plus prednisolone
Number of subjects: 134
Study 18544992 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 134
Study 15975314 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCBS herbs orally taken in addition to conventional treatment
Number of subjects: 88
Study 15975314 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with western medicine (WM) and Salvia injection
Number of subjects: 88
Study 12172089 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent reproductive health intervention (ARHI)
Number of subjects: 723
Study 12172089 — intervention group
Group type: COMPARATOR
Intervention: Community survey
Number of subjects: 723
Study 9669275 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dodecafluoropentane emulsion (EchoGen)
Number of subjects: 254
Study 9669275 — intervention group
Group type: COMPARATOR
Intervention: Active control (sonicated human albumin [Albunex])
Number of subjects: 254
Study 8090164 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant therapy (Curosurf, 200 mg/kg) plus nasal continuous positive airway pressure
Number of subjects: 68
Study 8090164 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure alone
Number of subjects: 68
Study 8090164 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant therapy (Curosurf, 200 mg/kg) plus nasal continuous positive airway pressure (excluding 17 infants with ratios <0.15)
Number of subjects: 68
Study 8090164 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure alone (excluding 17 infants with ratios <0.15)
Number of subjects: 68
Study 8090164 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant therapy
Number of subjects: 68
Study 2513717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg single dose
Number of subjects: 262
Study 2513717 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 3 g plus Probenecid 1 g single dose
Number of subjects: 262
Study 4421738 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 4421738 — intervention group
Group type: EXPERIMENTAL
Intervention: Codis
Number of subjects: 0
Study 4421738 — intervention group
Group type: EXPERIMENTAL
Intervention: Distalgesic
Number of subjects: 0
Study 4421738 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0
Study 4421738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 0
Study 4421738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciba 44,328
Number of subjects: 0
Study 4421738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after active analgesic)
Number of subjects: 0
Study 4421738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (colour effect)
Number of subjects: 0
Study 30148803 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral VEMP recording at 125 dB pe SPL
Number of subjects: 60
Study 30148803 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VEMP testing)
Number of subjects: 60
Study 28262598 — intervention group
Group type: EXPERIMENTAL
Intervention: AIMS (Adherence Improving self‐Management Strategy)
Number of subjects: 221
Study 28262598 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 221
Study 25866384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 10 sessions before surgery
Number of subjects: 128
Study 25866384 — intervention group
Group type: COMPARATOR
Intervention: Bariatric surgery alone
Number of subjects: 128
Study 24225155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy with electrons (21 Gy to the tumour bed during surgery)
Number of subjects: 1305
Study 24225155 — intervention group
Group type: COMPARATOR
Intervention: External radiotherapy (50 Gy in 25 fractions of 2 Gy, followed by a boost of 10 Gy in five fractions)
Number of subjects: 1305
Study 24225155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy with electrons
Number of subjects: 1305
Study 24225155 — intervention group
Group type: COMPARATOR
Intervention: External radiotherapy
Number of subjects: 1305
Study 21207053 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity resistance training with vascular restriction (LI-VRT)
Number of subjects: 37
Study 21207053 — intervention group
Group type: COMPARATOR
Intervention: High-intensity resistance training (HI-RT)
Number of subjects: 37
Study 21207053 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 37
Study 21207053 — intervention group
Group type: COMPARATOR
Intervention: Exercise groups (LI-VRT and HI-RT)
Number of subjects: 37
Study 19410624 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1-C1/Alhydrogel with CPG 7909 in saline
Number of subjects: 24
Study 19410624 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1-C1/Alhydrogel with CPG 7909 at 0,2 month interval
Number of subjects: 24
Study 19410624 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1-C1/Alhydrogel with CPG 7909 at 0,1 month interval
Number of subjects: 24
Study 17416113 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide 80 mg tablet from EMS Indústria Farmacêutica Ltda.
Number of subjects: 0
Study 17416113 — intervention group
Group type: COMPARATOR
Intervention: Diamicron 80 mg tablet from Servier do Brazil Ltda. (Control)
Number of subjects: 0
Study 17416113 — intervention group
Group type: COMPARATOR
Intervention: Diamicron 80 mg tablet from Servier (Ireland) Industries Limited (Control)
Number of subjects: 0
Study 15351936 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogens + 5 mg medroxyprogesterone acetate (HRT)
Number of subjects: 32
Study 15351936 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 32
Study 11529341 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine
Number of subjects: 142
Study 11529341 — intervention group
Group type: COMPARATOR
Intervention: 5% hyperbaric lidocaine
Number of subjects: 142
Study 11529341 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 142
Study 9661037 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole solution (200 mg)
Number of subjects: 30
Study 9661037 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyitraconazole solution (200 mg)
Number of subjects: 30
Study 9661037 — intervention group
Group type: COMPARATOR
Intervention: Capsule formulations (200 mg)
Number of subjects: 30
Study 9661037 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations (solution and capsules)
Number of subjects: 30
Study 7845778 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing mode
Number of subjects: 21
Study 7845778 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing mode
Number of subjects: 21
Study 29848468 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating4Two smartphone app
Number of subjects: 1330
Study 29848468 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal care
Number of subjects: 1330
Study 27109158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglioside (330g/day or 660g/day)
Number of subjects: 75
Study 27109158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 25480020 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume aerobic exercise (300 minutes/week)
Number of subjects: 400
Study 25480020 — intervention group
Group type: COMPARATOR
Intervention: Moderate volume aerobic exercise (150 minutes/week)
Number of subjects: 400
Study 22891528 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention (lectures and focus group discussions)
Number of subjects: 320
Study 22891528 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health education intervention)
Number of subjects: 320
Study 21095399 — intervention group
Group type: EXPERIMENTAL
Intervention: Stock metal trays
Number of subjects: 7
Study 21095399 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed-flow stock plastic trays
Number of subjects: 7
Study 21095399 — intervention group
Group type: EXPERIMENTAL
Intervention: Stock plastic trays
Number of subjects: 7
Study 21095399 — intervention group
Group type: COMPARATOR
Intervention: Custom trays with VPS impression materials
Number of subjects: 7
Study 18834506 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg
Number of subjects: 80
Study 18834506 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Number of subjects: 80
Study 16948483 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (VC) 3 g/d
Number of subjects: 18
Study 16948483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 18
Study 14753004 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric sleep
Number of subjects: 90
Study 14753004 — intervention group
Group type: EXPERIMENTAL
Intervention: Hofitol
Number of subjects: 90
Study 14753004 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric sleep plus hofitol
Number of subjects: 90
Study 10737699 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 pg of androstadienone
Number of subjects: 40
Study 10737699 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 9366314 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-magnesium citrate (42 mEq. potassium, 21 mEq. magnesium, and 63 mEq. citrate) daily for up to 3 years
Number of subjects: 64
Study 9366314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 9366314 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-magnesium citrate
Number of subjects: 64
Study 1489075 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with isobaric bupivacaine 0.5% at a dose of 0.5 mg/kg
Number of subjects: 40
Study 1489075 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia induced with thiopentone 2‐5 mg/kg, continued with low‐dose fentanyl (1‐2 micrograms/kg), oxygen/nitrous oxide/isoflurane (30/70/0.1‐0.5%), vecuronium
Number of subjects: 40
Study 2860271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural Corynebacterium parvum 7 mg
Number of subjects: 405
Study 2860271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 29526416 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-LGE quantification using a threshold of 8SD for peak TnI>50ng/mL
Number of subjects: 93
Study 29526416 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-LGE quantification using a threshold of 4SD for peak TnI>95ng/mL
Number of subjects: 93
Study 29526416 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-LGE quantification methods
Number of subjects: 93
Study 29526416 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with peak troponin levels
Number of subjects: 93
Study 28990590 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Health
Number of subjects: 364
Study 28990590 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight
Number of subjects: 364
Study 28990590 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 364
Study 27403931 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (sulfonylurea)
Number of subjects: 365
Study 27403931 — intervention group
Group type: COMPARATOR
Intervention: Clinical model (baseline values of HbA1c and disposition index)
Number of subjects: 365
Study 27403931 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide + genetic markers
Number of subjects: 365
Study 24739799 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg twice daily
Number of subjects: 15
Study 24739799 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin 2 mg twice daily
Number of subjects: 15
Study 22738096 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 76
Study 22738096 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 76
Study 20178952 — intervention group
Group type: EXPERIMENTAL
Intervention: Group recalling autobiographical episodes of conscientiousness and low openness to experience
Number of subjects: 3
Study 20178952 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 20178952 — intervention group
Group type: EXPERIMENTAL
Intervention: Group recalling autobiographical episodes of low conscientiousness and high openness to experience
Number of subjects: 3
Study 17673281 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of commercial PA facilities near homes
Number of subjects: 1556
Study 17673281 — intervention group
Group type: COMPARATOR
Intervention: None (control group with no commercial PA facilities nearby)
Number of subjects: 1556
Study 15829793 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter death to preservation time
Number of subjects: 1101
Study 15829793 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor age
Number of subjects: 1101
Study 17039194 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 20
Study 10206383 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (n=22)
Number of subjects: 75
Study 10206383 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (n=23)
Number of subjects: 75
Study 7822649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous injection system for delivering local anesthetic
Number of subjects: 0
Study 7822649 — intervention group
Group type: COMPARATOR
Intervention: Traditional delivery method of local anesthetic
Number of subjects: 0
Study 1972008 — intervention group
Group type: EXPERIMENTAL
Intervention: dapiprazole 0.5% eye drops
Number of subjects: 50
Study 1972008 — intervention group
Group type: COMPARATOR
Intervention: control eye (no dapiprazole)
Number of subjects: 50
Study 287556 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin-DNA (ADR-DNA)
Number of subjects: 0
Study 287556 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin-DNA (DNR-DNA)
Number of subjects: 0
Study 287556 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-DNA complexes
Number of subjects: 0
Study 30763142 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide (600 mg [two 300-mg tablets] twice daily)
Number of subjects: 1509
Study 30763142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1509
Study 30763142 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 1509
Study 28569078 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg/kg palonosetron
Number of subjects: 0
Study 28569078 — intervention group
Group type: COMPARATOR
Intervention: 3 × 150 μg/kg ondansetron
Number of subjects: 0
Study 25528694 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to real chocolate
Number of subjects: 0
Study 25528694 — intervention group
Group type: COMPARATOR
Intervention: Control stimuli
Number of subjects: 0
Study 25528694 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exposure and control groups
Number of subjects: 0
Study 23017464 — intervention group
Group type: EXPERIMENTAL
Intervention: Savoury food items (e.g., mashed potatoes, tortilla chips)
Number of subjects: 15
Study 23017464 — intervention group
Group type: EXPERIMENTAL
Intervention: Savoury food items (e.g., canned tomatoes, tortilla chips)
Number of subjects: 15
Study 23017464 — intervention group
Group type: EXPERIMENTAL
Intervention: Savoury food items
Number of subjects: 15
Study 21871095 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic arm therapy
Number of subjects: 20
Study 21871095 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 20
Study 20053238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (Int) group
Number of subjects: 210
Study 20053238 — intervention group
Group type: COMPARATOR
Intervention: Nonassessed Control (NAC) group
Number of subjects: 210
Study 20053238 — intervention group
Group type: COMPARATOR
Intervention: Assessed Control (AC) group
Number of subjects: 210
Study 16460244 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 65
Study 16460244 — intervention group
Group type: COMPARATOR
Intervention: Subpedicle connective tissue graft (CTG)
Number of subjects: 65
Study 15369206 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational activities developed by the authors (enhanced condition)
Number of subjects: 0
Study 15369206 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control condition)
Number of subjects: 0
Study 11138831 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dk/t hydrogel lenses on a 30‐night EW schedule
Number of subjects: 0
Study 11138831 — intervention group
Group type: COMPARATOR
Intervention: Low Dk/t hydrogel lenses on a 6‐night EW schedule
Number of subjects: 0
Study 11138831 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer to high Dk/t lenses after 12 months
Number of subjects: 0
Study 9124993 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T) monotherapy, daily dose of 12/1.5 g for an average of 10 days
Number of subjects: 33
Study 8354894 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1 alpha (IL-1 alpha) infusion
Number of subjects: 0
Study 3730024 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ifosfamide (500-mg gelatine capsules) at 1 g/m2
Number of subjects: 18
Study 3730024 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ifosfamide (500-mg gelatine capsules) at 2 g/m2
Number of subjects: 18
Study 3730024 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ifosfamide (Holoxan) at 1 g/m2
Number of subjects: 18
Study 3730024 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ifosfamide (Holoxan) at 2 g/m2
Number of subjects: 18
Study 30891654 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD with ablation
Number of subjects: 0
Study 30891654 — intervention group
Group type: COMPARATOR
Intervention: ICD with standard medical therapy alone
Number of subjects: 0
Study 30891654 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation as primary therapy (registry cohort)
Number of subjects: 0